Dabrafenib
[CAS# 1195765-45-7]

Identification

• Classification: Biochemical >> Inhibitor >> Mitogen-activated protein kinase (MAPK) >> Raf inhibitor
• Name: Dabrafenib
• Synonyms: N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
• Molecular Formula: C₂₃H₂₀F₃N₅O₂S₂
• Molecular Weight: 519.56
• CAS Registry Number: 1195765-45-7
• EC Number: 689-166-9
• SMILES: CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

Properties

• Solubility: >80 mg/mL (DMSO), <1 mg/mL (water)
• Density: 1.443

Safety Data

• Hazard Symbols: GHS08;GHS09 Warning
• Hazard Statements: H361f-H373-H400-H401
• Precautionary Statements: P203-P260-P273-P280-P318-P319-P391-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute hazardous to the aquatic environment	Aquatic Acute	1	H400
Chronic hazardous to the aquatic environment	Aquatic Chronic	2	H411
Specific target organ toxicity - repeated exposure	STOT RE	2	H373
Reproductive toxicity	Repr.	2	H361fd
Reproductive toxicity	Repr.	2	H361

Discovory and Applicatios

Dabrafenib is a targeted cancer therapy discovered by GlaxoSmithKline in the early 2000s. It emerged from research focused on finding inhibitors of the BRAF kinase, a protein involved in cell growth and division, which is often mutated in various cancers, most notably melanoma. The most common mutation, BRAF V600E, leads to uncontrolled cell proliferation. After extensive preclinical studies and clinical trials demonstrating significant efficacy and manageable safety profiles, dabrafenib received FDA approval in 2013 for the treatment of metastatic melanoma with BRAF V600E mutations. This discovery marked a significant advancement in the development of personalized cancer therapies, offering new hope for patients with specific genetic profiles.

Dabrafenib is primarily used in the treatment of melanoma with BRAF V600E mutations. As a BRAF inhibitor, it works by selectively targeting and inhibiting the mutant BRAF kinase, thereby interrupting the aberrant signaling pathways that promote cancer cell growth. This targeted mechanism makes dabrafenib particularly effective in shrinking tumors and controlling disease progression in patients with BRAF-mutant melanoma.

In clinical practice, dabrafenib is often used in combination with trametinib, a MEK inhibitor. This combination therapy has been shown to improve survival rates and delay disease progression compared to dabrafenib alone. The synergy between dabrafenib and trametinib helps overcome resistance that often develops with single-agent therapy, providing a more durable response.

Beyond melanoma, dabrafenib's applications extend to other cancers harboring BRAF V600E mutations. It has shown efficacy in treating non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer, expanding its therapeutic potential. The approval of dabrafenib for these indications has been a significant step forward in the management of these cancers, offering new options for patients with limited treatment choices.

Ongoing research is exploring the use of dabrafenib in combination with other targeted therapies and immunotherapies to further enhance its effectiveness and broaden its applicability. Additionally, studies are investigating biomarkers that can predict response to dabrafenib, aiming to personalize treatment and maximize therapeutic benefits.

The development of dabrafenib highlights the importance of precision medicine in oncology. By targeting specific genetic mutations, dabrafenib provides a tailored approach to cancer treatment, improving outcomes and offering new hope to patients with BRAF-mutant cancers. As research continues, dabrafenib's role in cancer therapy is expected to expand, contributing to more effective and personalized treatment strategies.